Assess the outlook for the PharmaVitae universe of leading Rx pharma companies to 2014, in terms of both sales and operating performance. Analyze the industry by peer set, balance of launches / expiries, and therapeutic and molecule type focus.
Datamonitor provides an overview of and profiles key hemophilia A and B pipeline products launching in the near future in the US and five major EU markets (France, Germany, Italy, Spain, and the UK).
This report provides an analysis of the orphan drug market. It comprises brands that have gained US FDA orphan drug approval, as well as Phase III pipeline candidates that have gained an orphan drug designation from the FDA.
Edit my basket
© Datamonitor 2012. All rights reserved
Terms & Conditions